Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors

Adnan, A.Kudachi, S.Ramesh, S.Prabhash, K.Basu, Sandip2020-11-252020-11-252019Nuclear Medicine Communications, 2019. Vol. 40 (9)http://hdl.handle.net/123456789/214295598 bytestext/htmlen177Lu-DOTATATEmediastinal neuroendocrine tumourneuroendocrine tumourpeptide receptor radionuclide therapythymic neuroendocrine tumourMetastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factorsArticle